Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTXNASDAQ:KPTINASDAQ:NXTCNASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$4.84-0.8%$4.46$3.39▼$16.00$52.41M0.759,100 shs44,205 shsKPTIKaryopharm Therapeutics$4.39+0.7%$5.09$3.51▼$17.40$37.93M0.2381,844 shs33,104 shsNXTCNextCure$0.68+4.8%$0.44$0.22▼$1.82$18.23M1.07111,022 shs368,516 shsPMVPPMV Pharmaceuticals$1.08-0.9%$0.96$0.81▼$1.82$56.11M1.43227,217 shs176,835 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics-0.82%+18.05%+34.44%-34.51%-57.88%KPTIKaryopharm Therapeutics+0.69%-2.23%-9.48%-34.96%-71.59%NXTCNextCure+4.72%+37.49%+53.17%-1.15%-53.36%PMVPPMV Pharmaceuticals-0.92%+11.34%+27.69%-14.29%-38.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.567 of 5 stars3.55.00.00.02.81.71.3KPTIKaryopharm Therapeutics3.9931 of 5 stars3.51.00.04.62.22.50.6NXTCNextCure4.6471 of 5 stars3.55.00.04.33.01.71.3PMVPPMV Pharmaceuticals2.4119 of 5 stars3.52.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00519.83% UpsideKPTIKaryopharm Therapeutics 3.00Buy$43.20884.05% UpsideNXTCNextCure 3.00Buy$3.50413.95% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50409.26% UpsideCurrent Analyst Ratings BreakdownLatest NXTC, KPTI, PMVP, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/13/2025KPTIKaryopharm TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.003/20/2025PMVPPMV PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/17/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$441K118.84N/AN/A$9.11 per share0.53KPTIKaryopharm Therapeutics$142.13M0.27N/AN/A($1.47) per share-2.99NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/APMVPPMV PharmaceuticalsN/AN/AN/AN/A$4.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)KPTIKaryopharm Therapeutics-$143.10M-$13.26N/AN/AN/A-52.62%N/A-39.58%8/5/2025 (Estimated)NXTCNextCure-$62.72M-$1.76N/AN/AN/AN/A-62.50%-53.67%7/30/2025 (Estimated)PMVPPMV Pharmaceuticals-$68.96M-$1.18N/AN/AN/AN/A-24.20%-21.67%8/6/2025 (Estimated)Latest NXTC, KPTI, PMVP, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/A5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A1.421.42KPTIKaryopharm TherapeuticsN/A1.702.93NXTCNextCureN/A9.079.07PMVPPMV PharmaceuticalsN/A13.9813.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%KPTIKaryopharm Therapeutics66.44%NXTCNextCure42.65%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics3.03%KPTIKaryopharm Therapeutics2.98%NXTCNextCure17.90%PMVPPMV Pharmaceuticals7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.37 millionNot OptionableKPTIKaryopharm Therapeutics3808.64 million122.72 millionOptionableNXTCNextCure9028.05 million24.28 millionOptionablePMVPPMV Pharmaceuticals5051.95 million47.81 millionOptionableNXTC, KPTI, PMVP, and AVTX HeadlinesRecent News About These CompaniesPMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare AdvancesMay 23, 2025 | quiverquant.comPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comWe're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateMay 18, 2025 | finance.yahoo.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.83%April 21, 2025 | aaii.comHere's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom FishingMarch 5, 2025 | zacks.comPMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals sees cash runway to end of 2026March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate HighlightsMarch 3, 2025 | globenewswire.comPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesFebruary 11, 2025 | globenewswire.comPMV Pharmaceuticals stock hits 52-week low at $1.32January 21, 2025 | msn.comPMV Pharmaceuticals files $200M mixed securities shelfNovember 22, 2024 | markets.businessinsider.comPMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerNovember 9, 2024 | markets.businessinsider.comPMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)October 25, 2024 | markets.businessinsider.comPMV Pharmaceuticals (PMVP) Gets a Buy from Craig-HallumOctober 25, 2024 | markets.businessinsider.comPMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical TrialOctober 23, 2024 | finance.yahoo.comPMV provides update on Phase 2, Phase 1b portions of PYNNACLE trialOctober 23, 2024 | markets.businessinsider.comPMV Pharma (NASDAQ:PMVP) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXTC, KPTI, PMVP, and AVTX Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$4.84 -0.04 (-0.82%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.67 -0.17 (-3.60%) As of 06/13/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Karyopharm Therapeutics NASDAQ:KPTI$4.39 +0.03 (+0.69%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.38 -0.01 (-0.14%) As of 06/13/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.NextCure NASDAQ:NXTC$0.68 +0.03 (+4.77%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.72 +0.03 (+4.99%) As of 06/13/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.PMV Pharmaceuticals NASDAQ:PMVP$1.08 -0.01 (-0.92%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.08 0.00 (0.00%) As of 06/13/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
